Genesis Molecular AI
Renamed from Genesis Therapeutics.
Data as of .
Company facts
-
Founded
2019
-
Headquarters
United States (Burlingame, CA)
-
Total funding
more than $280M before the 2026 Incyte equity
Latest funding round
- Round
- Strategic equity from Incyte (part of expanded collaboration)
- Date
- May 20, 2026
- Amount
- $40M
- Lead investor
- Incyte (strategic equity within the collaboration)
Drug discovery partners
1 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Incyte Pharma
Expanded collaboration and equity,
$120M upfront ($1B total potential)
Recent news
-
CTO Sergey Edunov, who led pretraining for Llama 2, 3 and 4, interviewed on AI:AM
-
Incyte collaboration expanded to $1B+
-
Expanded Incyte partnership; $120M upfront consideration
-
Renamed from Genesis Therapeutics and launches the Pearl structure prediction model
-
Incyte partnership on AI small molecules (2025 start)
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.